08:39 , Apr 3, 2019 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...
17:27 , Mar 22, 2019 |  BC Week In Review  |  Company News

argenx gets first milestone payment from AbbVie for immuno-oncology therapy

AbbVie started a Phase I trial of ABBV-151 to treat solid tumors, triggering a $30 million milestone payment to argenx. AbbVie Inc. (NYSE:ABBV) exercised an option in 2018 to exclusively license the antibody targeting leucine-rich...
16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient samples and mouse studies suggest an antibiotic cocktail or inhibiting IL22RA1 or IL-17A could help treat lung cancer. In tissue samples from patients with lung adenocarcinoma, levels of IL22RA1 were higher...
01:47 , Feb 8, 2019 |  BC Week In Review  |  Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Novo gets option to cardiovascular company Staten

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) gained an option to acquire Staten Biotechnology B.V. (Nijmegen, the Netherlands), including its lead candidate, STT-5058, in development to reduce cardiovascular risk in patients with hypertriglyceridemia. STT-5058 is an...
23:26 , Dec 17, 2018 |  BC Extra  |  Company News

Novo gets option to cardiovascular company Staten

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) received an option to acquire Staten Biotechnology B.V. (Nijmegen, the Netherlands) along with its lead candidate, STT-5058, which is in development to reduce cardiovascular risk in patients with hypertriglyceridemia....
18:08 , Dec 7, 2018 |  BC Week In Review  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:27 , Dec 4, 2018 |  BC Extra  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...